Ebene Magazine – Brainstorm Cell Therapeutics Inc. (NASDAQ: BCLI) is expected to report earnings of $ 0.27 per share

0
16
Ebene Magazine - Brainstorm Cell Therapeutics Inc. (NASDAQ: BCLI) is expected to report earnings of $ 0.27 per share

Log in to MarketBeat All Access to get access to all of MarketBeat’s research:

Analysts predict Brainstorm Cell Therapeutics Inc. (NASDAQ: BCLI) will make a profit for the current fiscal quarter, according to Zacks per share of ($ 0.27). Zero analysts have released estimates of Brainstorm Cell Therapeutics’ profits. Brainstorm Cell Therapeutics posted earnings of ($ 0.32) per share for the same quarter last year, a positive growth rate of 15.6% year over year. The company is expected to release its next earnings report on Thursday, May 6th.

According to Zacks, analysts expect Brainstorm Cell Therapeutics to post annual earnings of ($ 1.55) per share for the current fiscal year, with the EPS estimates are between ($ 2.10) and ($ 0.99). For the next fiscal year, analysts expect earnings of ($ 0.89) per share, with EPS estimates ranging between ($ 1.77) and $ 0.00. Zacks Investment Research’s average earnings per share are based on a survey of sell-side research firms involved in Brainstorm Cell Therapeutics.

Brainstorm Cell Therapeutics (NASDAQ: BCLI) last announced on Wednesday, April 3rd. February, its results announced. The biotech company reported earnings per share of $ 0.37 for the quarter, beating Zacks’ consensus estimate of $ 0.48 by $ 0.11.

Regardless, Maxim Group upgraded Brainstorm Cell Therapeutics from a « Hold » rating to a « Buy » rating in a report on Thursday, February 4th, with a price target of $ 12.00 for the company Several institutional investors have recently changed their positions in BCLI. JPMorgan Chase & Co. increased its stake in Brainstorm Cell Therapeutics by 3,585.7% in the fourth quarter. JPMorgan Chase & Co. now owns 392,417 shares in the biotechnology company, valued at $ 1,776,000, after acquiring an additional 381,770 shares last quarter. Voloridge Investment Management LLC increased its stake in Brainstorm Cell Therapeutics by 318.6% in the fourth quarter. Voloridge Investment Management LLC now owns 357,761 shares in the biotechnology company valued at $ 1,619,000 after acquiring an additional 272,294 shares last quarter. Walleye Capital LLC acquired a new stake in Brainstorm Cell Therapeutics in the fourth quarter valued at approximately $ 73,000. Squarepoint Ops LLC acquired a new stake in Brainstorm Cell Therapeutics for approximately $ 64,000 in the fourth quarter. Finally, Nuveen Asset Management LLC increased its stake in Brainstorm Cell Therapeutics by 16.0% in the fourth quarter. Nuveen Asset Management LLC now owns 123,624 shares in the biotech company, valued at $ 1,476,000, after acquiring an additional 17,040 shares last quarter. Hedge funds and other institutional investors own 21.58% of the company’s shares. (adsbygoogle = window.adsbygoogle || []). push ({});

The Brainstorm Cell Therapeutics share opened at $ 6.90 on Monday. The stock has a market capitalization of $ 246.47 million, a price to earnings ratio of -6.57, and a beta of 0.37. The stock has a 50-day moving average price of $ 5.80 and a 200-day moving average price of $ 9.53. Brainstorm Cell Therapeutics has a year low of $ 3.80 and a year high of $ 17.95.

Brainstorm Cell Therapeutics Inc, a biotechnology company, develops and commercializes autologous cell therapies for the treatment of neurodegenerative diseases. The company has the rights to develop and commercialize its NurOwn technology, which uses cell culture methods to induce autologous mesenchymal stem cells from bone marrow to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival and neurological Functionality Improve.

This instant message alert was generated by narrative science technology and financial data from MarketBeat to give readers the fastest, most accurate coverage. This story has been reviewed by the editorial staff of MarketBeat prior to publication. Please send any questions or comments about this story to [email protected]

There are more than 500 national retailers trading on the NYSE and NASDAQ. With the sheer number of large stores, warehouse clubs, chain restaurants, and other retail stores listed in public markets, it can be difficult to identify which retailers will outperform the market.

Fortunately, some of Wall Street’s top analysts have already done most of the work for us. Every year analysts make approximately 4,200 different recommendations for retail businesses. Analysts may not always get correct « buy » ratings, but it pays to take a close look when multiple analysts from different brokers and research firms give the same retailer a « buy » and « buy » rating.

This slideshow lists the 8 retail companies with the highest average analyst recommendations from Wall Street stock analysts for the past 12 months.

Fill out the form below to receive the latest headlines and analyst recommendations for your stocks with our free daily email To receive newsletters:

Sign up to MarketBeat All Access to get access to all of MarketBeat’s research:

Show the latest news, buy / sell ratings, SEC filings and insider deals for yours Shares on. Compare your portfolio performance against leading indices and get personalized stock ideas based on your portfolio.

Get stock ideas daily with the best Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. See what stocks are up to date on social media with MarketBeat’s Trending Stock Report.

Identify stocks that match your criteria with seven unique stock screeners. See what’s happening in the market with MarketBeat’s real-time news feed. Export data to Excel for your own analysis.

MarketBeat All Access subscribers can access Stock Screener, the Idea Engine, data export tools, research reports, and other premium tools.

Looking for new stock ideas? Would you like to see which stocks are moving? View our full range of financial calendars and market data tables for free.

Receive free world class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

MarketBeat enables individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, company buybacks, dividends, earnings, business reports, financial data, insider trading, IPOs, SEC filings, or stock splits, MarketBeat has the objective information you need to analyze stocks. Learn more.

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St # 105, Sioux Falls, SD 57103 | [Email protected] | (844) 978-6257
MarketBeat does not provide financial advice or make recommendations or offers to buy stocks or sell any securities. Learn more.
Don’t sell my information

© 2021 The market data provided will be delayed by at least 10 minutes and hosted by Barchart Solutions. The information is provided « as is » and for informational purposes only, not for commercial or advisory purposes, and is delayed. Please see the disclaimer for all delays and terms of use for exchanges. Basic company data from Zacks Investment Research. As a bonus for subscribing to our e-mail newsletters, you will also receive a free subscription to the Liberty Through Wealth e-newsletter. You can unsubscribe at any time.

Enter your email address below to receive a quick daily summary of upgrades, downgrades and new coverage from Analysts with MarketBeat.com’s FREE daily email newsletter.

Ref: https://www.marketbeat.com

QU’EN PENSEZ-VOUS?

[comment]

Laisser un commentaire, votre avis compte!

[gs-fb-comments] [comment-form]

Laisser un commentaire, votre avis compte!